146 related articles for article (PubMed ID: 9923547)
1. Pharmacokinetics of paclitaxel in an anephric patient.
Woo MH; Gregornik D; Shearer PD; Meyer WH; Relling MV
Cancer Chemother Pharmacol; 1999; 43(1):92-6. PubMed ID: 9923547
[TBL] [Abstract][Full Text] [Related]
2. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
Sonnichsen DS; Hurwitz CA; Pratt CB; Shuster JJ; Relling MV
J Clin Oncol; 1994 Mar; 12(3):532-8. PubMed ID: 7907130
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
[TBL] [Abstract][Full Text] [Related]
4. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
[TBL] [Abstract][Full Text] [Related]
5. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Drug Metab Dispos; 1999 Nov; 27(11):1300-5. PubMed ID: 10534315
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients.
Ye M; Zhu Z; Fu Q; Shen K; Li DK
Acta Pharmacol Sin; 2000 Jul; 21(7):596-9. PubMed ID: 11360664
[TBL] [Abstract][Full Text] [Related]
7. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias.
Woo MH; Relling MV; Sonnichsen DS; Rivera GK; Pratt CB; Pui CH; Evans WE; Pappo AS
Clin Cancer Res; 1999 Mar; 5(3):543-9. PubMed ID: 10100705
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of a 1-h paclitaxel infusion.
Mross K; Holländer N; Hauns B; Schumacher M; Maier-Lenz H
Cancer Chemother Pharmacol; 2000; 45(6):463-70. PubMed ID: 10854133
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
11. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2.
Dhanikula AB; Panchagnula R; Singh I; Kaur KJ; Kaul CL; Sekhon JS
Methods Find Exp Clin Pharmacol; 2001 Mar; 23(2):93-8. PubMed ID: 11484417
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
19. Disposition kinetics of dibekacin in patients with renal failure and in patients undergoing hemodialysis.
Arancibia A; Baillarie D; Bravo M; Chávez J
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):623-7. PubMed ID: 8688988
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Doz F; Gentet JC; Pein F; Frappaz D; Chastagner P; Moretti S; Vassal G; Arditti J; Tellingen OV; Iliadis A; Catalin J
Br J Cancer; 2001 Mar; 84(5):604-10. PubMed ID: 11237379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
